Drugs / ADU-S100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03172936 | Sep 2017 → Dec 2020 | lymphoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02675439 | Apr 2016 → Dec 2019 | — | Chinook Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03937141 | Aug 2019 → May 2021 | head and neck squamous cell carcinoma | Chinook Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADU-S100 | “MIW 815 (ADU-S100) is a STING agonist” NCT03172936 ↗ |
| Known as | CDN AGONIST ADU-S100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297688 ↗ |
| Known as | MIW 815 | “MIW 815 (ADU-S100) is a STING agonist” NCT03172936 ↗ |
| Known as | MW-815 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297688 ↗ |
| Action | Activate | “Stimulator of interferon genes protein agonist” CHEMBL4297688 ↗1“MIW 815 (ADU-S100) is a STING agonist” NCT03172936 ↗ |
| Modality | Other / unclassified | “Aduro's CDN ADU-S100 monotherapy was also disappointing (NCT03172936).” PMID 32823563 ↗ Aug 2020 |
| Route | Other | “ADU-S100 administered intratumorally” NCT02675439 ↗ |
| Target | STING1 | “Stimulator of interferon genes protein agonist” CHEMBL4297688 ↗ |